论文部分内容阅读
目的观察纤溶酶联合血栓通治疗缺血性脑卒中的临床效果。方法选取该院收治的缺血性脑卒中患者122例,按照患者住院尾号奇偶数分成观察组和对照组各61例。观察组给予纤溶酶联合血栓通治疗,对照组给予单纯纤溶酶治疗,对比2组临床疗效及不良反应情况。结果观察组总有效率为96.72%高于对照组的72.13%,差异有统计学意义(χ~2=14.845,P<0.05)。治疗后2组均未发生不良反应。结论纤溶酶联合血栓通治疗缺血性脑卒中疗效显著,且治疗安全、可靠,具有重要的临床价值。
Objective To observe the clinical effect of plasmin combined with Xueshuantong on ischemic stroke. Methods 122 cases of ischemic stroke admitted to our hospital were selected and divided into observation group and control group according to the odd and even number of hospitalization tail end. The observation group was given plasmin combined with thrombus and the control group was treated with plasmin alone. The clinical efficacy and adverse reactions of the two groups were compared. Results The total effective rate in observation group was 96.72% higher than that in control group (72.13%), the difference was statistically significant (χ ~ 2 = 14.845, P <0.05). No adverse reactions occurred in both groups after treatment. Conclusion The combination of thrombolytic and thrombosis is effective in treating ischemic stroke, and the treatment is safe and reliable, which has important clinical value.